PLYMOUTH, Minn., Jan. 28, 2015 (GLOBE NEWSWIRE) -- Entellus Medical, Inc., a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients in the physician office setting or operating room, announced today the pricing of its initial public offering of 4,603,580 shares of its common stock at an initial public offering price of $17.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "ENTL" on January 29, 2015. In addition, Entellus Medical has granted the underwriters a 30-day option to purchase up to an additional 690,537 shares of common stock at the same price. The offering is expected to close on February 3, 2015, subject to customary closing conditions.
BofA Merrill Lynch and Piper Jaffray are acting as joint book-running managers for the offering. William Blair and Canaccord Genuity are acting as co-managers.
A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (SEC) and was declared effective by the SEC on January 28, 2015. The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the prospectus relating to and describing the offering may be obtained by contacting BofA Merrill Lynch at 222 Broadway, New York, NY 10038, Attention: Prospectus Department or by e-mail at dg.prospectus_requests@baml.com or Piper Jaffray at 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Equity Capital Markets, by telephone at 800-747-3924 or by e-mail at prospectus@pjc.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.